Azmi Nabulsi - Feb 27, 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role: Chief Operating Officer
Signature: /s/ Molly Henderson, Attorney-in-Fact for Azmi Nabulsi
Stock symbol: PHAT
Transactions as of: Feb 27, 2025
Transactions value $: $0
Form type: 4
Date filed: 3/3/2025, 05:13 PM
Previous filing: Jan 23, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHAT	Common Stock	Award	$0	+79.2K	+33.93%	$0.00	313K	Feb 27, 2025	Direct	F1
holding	PHAT	Common Stock						3.58K	Feb 27, 2025	By 401(k)
holding	PHAT	Common Stock						786K	Feb 27, 2025	By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PHAT	Stock Option (Right to Buy)	Award	$0	+55K		$0.00	55K	Feb 27, 2025	Common Stock	55K	$5.76	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2	The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.